MOESM2 of Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

Descripción

Additional file 2. This file includes all the references screened in the systematic review and the reason for exclusion.

Datos disponibles	22 oct 2019
Editor	figshare

Identificador de objetos digitales
10.6084/m9.figshare.10022105

1 Artículo

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases
Sampayo-Cordero, M., Miguel-Huguet, B., Pardo-Mateos, A., Malfettone, A., Pérez-García, J., Llombart-Cussac, A., Cortés, J., Moltó-Abad, M., Muñoz-Delgado, C., Pérez-Quintana, M. & Pérez-López, J., 21 oct 2019, En: Orphanet Journal of Rare Diseases. 14, 1, 230.
Producción científica: Contribución a una revista › Artículo › Investigación › revisión exhaustiva

Acceso abierto
18 Citas (Scopus)

Citar esto

Sampayo-Cordero, M. (Creador), Miguel-Huguet, B. (Colaborador), Pardo-Mateos, A. (Creador), Malfettone, A. (Creador), Pérez Garcia, J. I. (Creador), Llombart-Cussac, A. (Creador), Cortés, J. (Creador), Moltó-Abad, M. (Creador), Muñoz-Delgado, C. (Creador), Pérez-Quintana, M. (Creador), Pérez-López, J. (Creador) (22 oct 2019). MOESM2 of Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases. figshare. 10.6084/m9.figshare.10022105